AmBisome gains marketing approval in Israel.BOULDER, Colo.--(BUSINESS WIRE)--May 25, 1995--NeXstar Pharmaceuticals Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :NXTR), acting through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , Vestar Inc., announced today that the Israeli Ministry of Health had given final marketing approval to AmBisome, the company's liposomal formulation of amphotericin B amphotericin B (ăm'fətĕr`ĭsĭn), antibiotic that halts the growth of several disease-causing fungi. Discovered in 1956, it is produced by bacteria of the genus Streptomyces. , for commercial sales in Israel. AmBisome, the world's only commercial liposomal formulation of amphotericin B, is indicated for the treatment of life-threatening systemic systemic /sys·tem·ic/ (sis-tem´ik) pertaining to or affecting the body as a whole. sys·tem·ic adj. 1. Of or relating to a system. 2. fungal infections Fungal infections Several thousand species of fungi have been described, but fewer than 100 are routinely associated with invasive diseases of humans. that fail to respond to amphotericin B therapy. Israel becomes the 17th country to approve AmBisome. "We are delighted that AmBisome has received approval in Israel," said Patrick J. Mahaffy, NeXstar's president and chief executive officer. "This latest addition to the growing list of approvals shows once again that AmBisome is a safe and effective drug that fills a critical need in the care and management of life-threatening systemic fungal infections." NeXstar Pharmaceuticals Inc. is an integrated pharmaceutical company engaged in the discovery, development, manufacturing and marketing of products to treat life-threatening diseases. The company has headquarters in Boulder, research, development and manufacturing facilities in Boulder, San Dimas, Calif., and Antwerp, Belgium, and marketing subsidiaries in several European countries. CONTACT: NeXstar Pharmaceuticals, Boulder Joseph Alper, 303/546-7717 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion